News and views from the world of clinical oncology and hematology
Joined December 2009
- Tweets 35,026
- Following 4,484
- Followers 62,369
- Likes 910
9,202 Photos and videos
๐ฅ๏ธ #ASCOAI: This week in #AI and #oncology
The ASCO AI News Brief covers:
๐น Brain metastasis risk prediction
๐น AI-enabled clinical trial site selection presented at #ASCO26
๐น New research on LLM clinical reasoning performance
๐ฅ Watch here: ascoai.org/videos/weekly-briโฆ
3
3
532
๐งฌ A new era in #pancreaticcancer?
In this commentary, Drs. Ajay Prakash & Emil Lou (@cancerassassin1) examine how the phase III RASolute 302 trial positions daraxonrasib as a potential new standard in KRAS-mutant metastatic pancreatic cancer.
Read more โก๏ธ ascopost.com/issues/june-10-โฆ
2
4
9
748
๐ญ๐น What does it take for a #cancerprevention program to survive after its founder is gone?
In this powerful reflection, Danta Bien-Aimรฉ, BSN, RN, MMSc-GHD, explores the challenges of sustaining #cervicalcancer screening and treatment access in Haiti.
๐ ascopost.com/issues/june-10-โฆ
1
376
Jun 12
๐จ #FDAApproval: The @US_FDA approved capivasertib (Truqap) with abiraterone and prednisone for PTEN-deficient metastatic #ProstateCancer.
Approval based on the phase III CAPItello-281 trial, which showed improved radiographic PFS.
๐ ascopost.com/news/june-2026/โฆ
1
5
8
725
Jun 12
๐ง #ASCOAI: CNSPredict, a machine learning clinicogenomic model, identified patients with metastatic #breastcancer at high risk for brain metastases, including a subgroup with a 26% 2-year incidence rate.
๐ฃ๏ธ Presented by Luke R.G. Pike, MD, at #ASCO26
๐ ascoai.org/articles/2026/06/โฆ
8
9
1,121
Jun 12
๐จ #FDAApproval: The @US_FDA approved belzutifan (Welireg) pembrolizumab (Keytruda) for the adjuvant treatment of intermediate-high/high-risk clear cell #RCC following nephrectomy.
Approval based on findings from the phase III LITESPARK-022 trial.
๐ ascopost.com/news/june-2026/โฆ
7
702
Jun 12
๐ก Better patient engagement could strengthen #cancerresearch. The Participant Engagement Portal from @ALLIANCE_org enabled communication, high satisfaction & patient data collection to support clinical trials.
๐ฉโโ๏ธ Norah Crossnohere, PhD, MHS | @JNCI_Now
๐ ascopost.com/news/june-2026/โฆ
3
1
522
Jun 12
๐บ Even low levels of alcohol consumption may carry health risks.
A large analysis linked alcohol use to increased risks of cancer, heart disease, and premature death
โก๏ธ Risk rises as intake increases
๐น Kevin Shield, PhD | @JSADJournal
Learn more ๐ ascopost.com/news/june-2026/โฆ
1
5
5
832
Jun 12
๐ Could #GLP1 RAs help reduce #cancer risk?
๐ observational data found a significantly lower incidence of obesity-related cancers among GLP-1 RA users, with the greatest reduction seen with tirzepatide.
๐น Aparna A. Kamat, MD | @Annals_Oncology
๐ ascopost.com/news/june-2026/โฆ
3
6
10
1,388
Jun 11
๐ฅ๏ธ #ASCOAI: #AI isnโt just identifying biomarkers, itโs helping ensure patients get tested for them.
At #ASCO26, @MMarmarelis & @ravi_b_parikh discuss how an AI-enabled decision support system improved biomarker testing rates in early-stage #NSCLC.
๐ฅ ascoai.org/videos/newsreels/โฆ
1
2
672
Jun 11
๐ฉธ Phase III MajesTEC-9 highlights the promise of subcutaneous teclistamab in #MultipleMyeloma. Compared with PVd/Kd, teclistamab significantly improved PFS and OS in patients with relapsed/refractory disease.
๐น Cyrille Touzeau, MD, PhD | @NEJM | #ASCO26
ascopost.com/news/june-2026/โฆ
3
5
823
Jun 11
๐ Five-year follow-up from the WSG TP-II trial supports a de-escalated approach in HR /HER2 early #breastcancer.
5-year OS with neoadjuvant trastuzumab/pertuzumab plus:
๐นEndocrine Therapy = 100%
๐นPaclitaxel = 98%
๐จโโ๏ธ Oleg Gluz, MD | @JCO_ASCO
๐ ascopost.com/news/june-2026/โฆ
1
2
8
918
Jun 11
Can SABR offer a long-term option for patients with RCC who are not surgical candidates?
5๏ธโฃ-year results from FASTRACK and FASTRACK II:
๐น98% local control
๐น1 local progression
๐นNo grade 4 AEs
๐ฉบ Shankar Siva, MBBS, PhD | @TheLancetOncol | #KidneyCancer
ascopost.com/news/june-2026/โฆ
3
3
532
Jun 10
๐ฅ๏ธ #ASCOAI: Can #AI support complex clinical reasoning?
A study in @ScienceMagazine found @OpenAIโs o1 model outperformed physicians across several diagnostic and management reasoning tasks
โก๏ธ Potential for AI as a clinical decision support tool.
๐ ascoai.org/articles/2026/06/โฆ
1
2
3
904
Jun 10
๐งฌ For patients with metastatic HRR-altered #prostatecancer, the phase III TALAPRO-3 study delivered a significant PFS benefit.
โก At 3 years: ๏ธ77% progression-free with talazoparib enzalutamide vs 56% with enzalutamide alone
๐น @neerajaiims | @NEJM
๐ ascopost.com/news/june-2026/โฆ
2
4
905
Jun 10
๐ถ New #survivorship data suggest music therapy may be a powerful tool for anxiety management.
In the MELODY trial, music therapy matched CBT for reducing anxiety among cancer survivors, and improved fatigue, insomnia, mood, and quality of life.
๐ ascopost.com/news/june-2026/โฆ
3
540
Jun 10
The latest issue of The ASCO Post is LIVE!
Featuring coverage of:
๐น Practice-changing #ASCO26 data
๐น Expert perspectives on emerging standards of care
๐น Emerging #AI concepts in oncology
๐น Thoughts on cannabis use and #cancer
Read the full issue ๐ ascopost.com/issues/june-10-โฆ
1
393
Jun 9
๐ฅ๏ธ #ASCOAI: #AI isn't just transforming treatment decisions, it may also help us understand how decisions are made.
At #ASCO26, @aaronbcohen & @ravi_b_parikh discussed using LLMs to analyze clinician-patient discussions about landmark trial findings.
๐ ascoai.org/videos/newsreels/โฆ
1
3
2
566
Jun 9
๐ In the largest, multinational analysis of external beam RT in early-stage #HCC, survival outcomes were comparable to surgery, ablative therapies.
โก๏ธ Supports broader role for RT in treatment planning
๐บ Maria Reig, MD, PhD | @JCO_ASCO
Explore findings: ascopost.com/news/june-2026/โฆ
4
5
832
Jun 9
๐ฆ Real-world evidence may help improve ADC safety
Researchers found infection and hematologic AE risks varied substantially across antibody-drug conjugates, underscoring the importance of proactive monitoring.
๐ธJan et al | @Cancers_MDPI
Learn more: ascopost.com/news/june-2026/โฆ
2
3
5
777